S-740792 for Healthy Adults
Palo Alto (17 mi)Age: 18 - 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Recruiting
Sponsor: Shionogi
No Placebo Group
Trial Summary
What is the purpose of this trial?This is a 2-part study of S-740792 in healthy adult participants. Part 1 (single-ascending-dose) will investigate the safety, tolerability, and pharmacokinetics (PK) of S-740792. Part 2 (multiple-ascending-dose) will investigate the safety, tolerability, and PK of S-740792, in addition, the effect of multiple doses of S-740792 on the PK of midazolam.
Is the drug S-740792 a promising treatment for healthy adults?The information provided does not directly address the effectiveness or promise of the drug S-740792 for healthy adults. The articles focus on obesity and related health issues, but do not mention S-740792 or its potential benefits.2691415
What safety data is available for S-740792?The provided research does not contain specific safety data for S-740792. The articles focus on designer drugs, synthetic cannabinoids, and new psychoactive substances, but do not mention S-740792 or provide relevant safety data for it.710111213
Do I have to stop taking my current medications for this trial?Yes, participants who require medication or other treatments are excluded from the trial.
What data supports the idea that S-740792 for Healthy Adults is an effective drug?The available research does not provide any specific data on the effectiveness of S-740792 for Healthy Adults. Instead, it discusses other treatments for conditions like gastroesophageal reflux disease (GERD) and non-erosive reflux disease (NERD). For example, proton pump inhibitors (PPIs) are mentioned as a common treatment for these conditions, although patients with NERD often respond less effectively to PPIs compared to those with erosive reflux disease. Without specific data on S-740792, we cannot determine its effectiveness compared to these other treatments.13458
Eligibility Criteria
This trial is for healthy adults. Specific details about who can join are not provided, but typically participants should have no significant health issues and be within a certain age range.Exclusion Criteria
I haven't used tobacco or nicotine products in the last 6 months.
Treatment Details
The study tests S-740792 in two parts: one part checks the safety and how the body processes a single dose; another part looks at what happens with repeated doses and how it affects another drug called midazolam.
2Treatment groups
Experimental Treatment
Group I: Part 2 (Multiple Ascending Dose)Experimental Treatment3 Interventions
Participants will receive S-740792 or placebo, in addition to midazolam.
Group II: Part 1 (Single Ascending Dose)Experimental Treatment2 Interventions
Participants will receive S-740792 or placebo.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Fortrea Clinical Research Unit, Inc.Daytona Beach, FL
Loading ...
Who is running the clinical trial?
ShionogiLead Sponsor
References
Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. [2023]To evaluate the long-term efficacy and safety of omeprazole in patients with gastroesophageal reflux disease resistant to treatment with histamine-2 (H2)-receptor antagonists.
Obesity: assessment and intervention for primary care practice. [2004]The 1976-1980 National Health and Nutrition Examination Survey revealed that an estimated 34 million adults (26%) between the ages of 20 and 75 are obese. The health implications of obesity are well known and contribute to the increased morbidity and early mortality in those who are affected. As a result, obesity has become a public health concern that has been targeted as a national health objective in Healthy People 2000. The overall health objective, related to the problem of overweight in adults, is to reduce the prevalence from 26% to
Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. [2022]Gastroesophageal reflux disease (GERD) is difficult to control with medical therapy in neurologically impaired children. The gamma-aminobutyric acid type B receptor agonist baclofen was recently reported to reduce reflux in adult patients with GERD by reducing the incidence of transient lower esophageal sphincter relaxations. The current study was undertaken to investigate the effects of baclofen on GERD in neurologically impaired children.
Treatment of uncomplicated reflux disease. [2019]Uncomplicated reflux disease comprises the non-erosive reflux disease (NERD) and erosive reflux disease (ERD). The objectives of treatment are the adequate control of symptoms with restoration of quality of life, healing of lesions and prevention of relapse. Treatment of NERD consists in the administration of proton pump inhibitors (PPI) for 2-4 wk, although patients with NERD show an overall poorer response to PPI treatment than patients with ERD owing to the fact that patients with NERD do not form a pathophysiologically homogenous group. For long-term management on-demand treatment with a PPI is probably the best option. In patients with ERD, therapy with a standard dose PPI for 4-8 wk is always recommended. Long-term treatment of ERD is applied either intermittently or as continuous maintenance treatment with an attempt to reduce the daily dosage of the PPI (step-down principle). In selected patients requiring long-term PPI treatment, antireflux surgery is an alternative option. In patients with troublesome reflux symptoms and without alarming features empirical PPI therapy is another option for initial management. Therapy should be withdrawn after initial success. In the case of relapse, the long-term care depends on a careful risk assessment and the response to PPI therapy.
Optimal maintenance therapy in patients with non-erosive reflux disease reporting mild reflux symptoms--a pilot study. [2013]This pilot study aimed at finding trend for further investigation of the optimal maintenance therapy with lansoprazole in patients with non-erosive reflux disease (NERD) suffering from mild symptoms.
State-specific prevalence of obesity among adults--United States, 2007. [2009]Obesity is associated with reduced quality of life, development of serious chronic conditions such as heart disease and diabetes, increased medical care costs, and premature death. A Healthy People 2010 objective is to reduce to 15% the proportion of adults who are obese. In 2005, no state met this target, and (based on self-reported height and weight) 23.9% of adults in the United States were obese. To update 2005 estimates of the prevalence of obesity in adults, CDC analyzed data from the 2007 Behavioral Risk Factor Surveillance System (BRFSS) survey. The results of that analysis indicated that 25.6% of respondents overall in 2007 were obese; the prevalence of obesity among adults remained above 15% in all states and was above 30% in Alabama, Mississippi, and Tennessee. Enhanced collaborative efforts among national, state, and community groups are needed to establish, evaluate, and sustain effective programs and policies to reduce the prevalence of obesity in the United States.
Designer drugs 2015: assessment and management. [2022]Recent designer drugs, also known as "legal highs," include substituted cathinones (e.g., mephedrone, methylone, and methylenedioxypyrovalerone, often referred to as "bath salts"); synthetic cannabinoids (SCs; e.g., Spice); and synthetic hallucinogens (25I-NBOMe, or N-bomb). Compound availability has evolved rapidly to evade legal regulation and detection by routine drug testing. Young adults are the primary users, but trends are changing rapidly; use has become popular among members of the military. Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. Treatment of acute intoxication involves supportive care targeting manifesting signs and symptoms. Long-term treatment of designer drug use disorder can be challenging and is complicated by a lack of evidence to guide treatment.
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. [2018]The potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer clinical advantages over conventional therapy for acid-related disorders.
Are Obese Individuals with no Feature of Metabolic Syndrome but Increased Waist Circumference Really Healthy? A Cross Sectional Study. [2017]Patients displaying the metabolically healthy but obese phenotype have an intermediate cardiometabolic prognosis compared to normal weight healthy and metabolically unhealthy obese subjects. We aimed to evaluate the proportion of patients with a definite metabolically healthy obese phenotype and better characterize them.
Evolution of clinical characteristics and outcomes of synthetic cannabinoid receptor agonist exposure in the United States: analysis of National Poison Data System data from 2010 to 2015. [2019]New synthetic cannabinoid receptor agonists (SCRAs) are synthesized each year to evade US governmental regulation and sold for recreational use. Our aim was to estimate the changes in the clinical effects and patient disposition associated with SCRA exposure from 2010 to 2015.
Regional trends in suspected synthetic cannabinoid exposure from January 2016 to September 2019 in the United States. [2022]The unpredictable physiologic and pharmacologic effects of synthetic cannabinoids (SCs) are continuously changing as the chemical structure of SCs evolve to avoid classification as a Schedule I drug under the Controlled Substances Act in the U.S. This results in unpredictable pharmacologic effects and subsequent sequelae. Little is known about national or regional trends of SC clusters. The objective of this study is to investigate trends in SC exposure using emergency department (ED) syndromic data.
Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. [2021]Over the last decade, new psychoactive substances (NPS) have continuously been the focus of the international society since their emergence on the illicit drug market. NPS can be classified into six groups including; synthetic cannabinoid receptor agonists (SCRAs), stimulants, opioids, dissociatives, sedatives/hypnotics, and classic hallucinogens with psychoactive effects. These are sold as "herbal incense," "bath salts," "legal highs," and "research chemicals". They can be synthesized easily with slight changes in the chemical moieties of known psychoactive substances. NPS are sold worldwide via on- and off-line markets without proper scientific evaluation regarding their safety or harmfulness. Abuse of NPS poses a serious public health issue, and systematic studies on their adverse effects are lacking. Therefore, it would be meaningful to collect currently available data in order to understand NPS and to establish viable solutions to cope with the various health issues related to them. In this article, we reviewed the general pharmacological characteristics, recent findings, and adverse effects of representative NPS; SCRAs. SCRAs are known as the most commonly abused NPS. Most SCRAs, cannabinoid receptor 1 and cannabinoid receptor 2 agonists, are often associated with severe toxicities, including cardiotoxicity, immunotoxicity, and even death, unlike natural cannabinoid Δ9-Tetrahydrocannabinol.
Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions. [2022]The purpose of this narrative review is to describe the current use environment of both natural and synthetic cannabinoids while providing context for cannabinoid chemistry and pharmacology. In addition to a long history of recreational and nonmedical use, natural cannabinoids are increasingly used as prescription products, through medical cannabis programs, and as consumer health products. Despite anecdotal safety evidence, cannabis and cannabinoids are pharmacologically complex and pose risks for adverse drug events and drug-drug interactions. Synthetic cannabinoids, particularly agonists of cannabinoid receptors, are more potent than natural cannabinoids and can lead to more severe reactions and medical emergencies. This review provides a summary of approved uses and an overview of mechanisms of action for adverse drug events with natural and synthetic cannabinoids. Clinical considerations for special populations that may be at heightened risk for drug-drug interactions and adverse drug events while using natural or synthetic cannabinoids are examined, and recommendations are provided.
Trends in the prevalence of metabolically healthy and unhealthy obesity in the US adult population: analysis of eight NHANES cross-sectional survey cycles, 1999-2014. [2022]To exam the time trend of the prevalence of metabolically healthy obesity (MHO) in the US adult population.
Association of Healthy Lifestyle Factors and Obesity-Related Diseases in Adults in the UK. [2023]A healthy lifestyle is associated with a reduced risk of cardiovascular disease in adults with obesity. Little is known about the associations between a healthy lifestyle and the risk of other obesity-attributable diseases in this population.